Company Overview and News

13
Resource Sector Digest: Final Curtain For Nevsun?

2018-09-11 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
OCANF EMRRF LUNMF CNL MUN NSU FNLPF TGB THO MUX.RTWI MAG EVM MUNMF MUX SEMFF NEVDF ABX TAHO GPL MUX OKSWF CDEUW BGMZF DRGDF CDE LYDIF NCU OSKGF MAG APR APRLY TKO EXK NEM CPNFD CGOOF LUNCF GSV TECK DGC EDVVF OR TCKRF EDR GG EDV ABX EDVMF DPMLF LUN EVR

6
Gold Standard Closes C$10,725,000 Financing

2018-09-05 globenewswire
VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Gold Standard Ventures Corp. (TSX: GSV, NYSE AMERICAN: GSV) (“Gold Standard” or the “Company”) is pleased to announce that it has closed the non-brokered private placement previously announced on August 28, 2018 (the “Private Placement”) for aggregate gross proceeds of C$10,723,347 following the issuance of 5,230,901 common shares in the capital of the Company (“Shares”) at a price of C$2.
OCANF OGC OGC G OGDCF GSV GG

4
Record Short Position In Gold Is About To Get Wiped Out

2018-08-28 seekingalpha
Don't be shaken out of your long-term precious metal positions especially now when all the fundamentals are lining up.
OCANF GGIFF NSRPF NVO GG GTGDF

3
CANADA STOCKS-TSX gains in broad rally due to NAFTA optimism

2018-08-27 reuters
(Reuters) - Canada’s main stock index advanced on Monday in a broad-based rally on hopes that the trade negotiators of the United States and Mexico would arrive at a common ground on the North American Free Trade Agreement. * At 9:33 a.m. ET (13:33 GMT), the Toronto Stock Exchange’s S&P/TSX composite index was up 86.87 points, or 0.53 percent, at 16,442.92.
OCANF CVE ACBFF PVG CGC SU ACB PVG APH CNQ WEED CVE OGDCF APHQF SU

 
Best Drill Interceptions In The Mining Sector For The Week Ended 19 August 2018

2018-08-24 seekingalpha
Solgold on track with goal for mineral resource of 10 million tonnes of copper and 25 million ounces of gold at Cascabel.
OCANF GUY SLGGF GYGC SYIFD GUYFF

1
Diggers and Dealers Mining Forum gold plays to make up 21% of presenters

2018-08-05 proactiveinvestors.com.au
Diggers and Dealers Mining Forum 2018 will welcome a pack of gold plays to the stage this week to speak about their companies and the precious metal. Here’s who’s going.
ELKMF OCANF PILBF RMS EVN GCY SCEXF SNDFY WAF NST DCN AU IGO AULGF RSG OGC GOR LONCF MSR RMGGF SFR SBM AGG CAHPF PLS WFRSF IIDDY RGRNF ORG PNR LN NESRF SFRRF RMGGY RRL OGDCF NHRNY CANWF RMLRF SAR

 
Oceanagold Corporation 2018 Q2 - Results - Earnings Call Slides

2018-07-27 seekingalpha
The following slide deck was published by Oceanagold Corporation in conjunction with their 2018 Q2 earnings call.
OCANF OGDCF

 
Oceanagold Corporation (OGDCF) CEO Mick Wilkes on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Good morning, and good afternoon, ladies and gentlemen, and welcome to OceanaGold 2018 Second Quarter Results Webcast and Conference Call. [Operator Instructions] This call is being recorded on July 26, at 5:30 p.m., Eastern Standard Time.
OCANF OGDCF

 
NuLegacy Closes Initial Tranche of 8.5 Million Units

2018-07-19 globenewswire
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
OCANF ABX OGDCF NULGF ABX

 
NuLegacy Gold Arranges C$3.0 Million C$0.20/Unit Financing

2018-07-05 globenewswire
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
OCANF ABX OGDCF NULGF ABX

23
Leagold: A Brand New Mid-Tier Gold Miner With A More Than 100% Near-Term Upside Potential

2018-06-20 seekingalpha
Leagold should produce 420,000-475,000 toz gold at an AISC around $930/toz in 2018, however, its production should grow to the 700,000 toz level by 2020.
OCANF SCGLF AUY YRI EDVVF EDVMF SCGLY EVR GLE GG HTXFF EDV

 
OceanaGold: Short-Term Risks Or Long-Term Benefits - A Classic Dilemma

2018-05-05 seekingalpha
In my opinion, this underperformance results from a few specific risks carried by the company; in this article I am discussing these risks.
OCANF

 
Cartier IP Survey Outlines 4km Long Chargeability Anomaly Marking Major Epithermal System at Big Easy Property, Newfoundland

2018-05-01 globenewswire
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Cartier Iron Corporation (CSE:CFE) (“Cartier Iron”), is pleased to announce the successful completion of a 48-line kilometre Induced Polarization/Resistivity (IP/Res) survey at the Big Easy Property (“Big Easy”) by MES Geophysics of St. John’s, Newfoundland under the direction of Dr. Chris Hale, P.Geo., Chief Geophysicist for Cartier Iron. Big Easy is located approximately 20 kilometres northwest of the town of Clarenville, about 200km northwest of St.
OCANF OGDCF

 
Cartier Iron Provides Update on Exploration Program at Big Easy Property, Newfoundland

2018-03-27 globenewswire
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Cartier Iron Corporation (CSE:CFE) (“Cartier Iron”), is pleased to announce the completion of line cutting and commencement of the 56-line kilometre Induced Polarization/Resistivity Survey (“IP/Res”) at the Big Easy Property (“Big Easy”) in Newfoundland. Big Easy is located approximately 20 kilometres (km) northwest of the town of Clarenville, about 200km northwest of St.
OCANF OGDCF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 675222954